• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis prevention

Crizanlizumab (SEG101), Novartis‘ investigational compound for sickle cell disease (SCD), received breakthrough therapy designation from the U.S. Food and Drug Administration for its potential to prevent vaso-occlusive crises (VOCs).

The FDA designation was granted based on promising data from the company’s multicenter, randomized, double-blind, 52-week, Phase 2 SUSTAIN clinical trial (NCT01895361).

“Painful sickle cell crises matter because they can disrupt patients’ lives, and often require hospital visits and medical attention,” Samit Hirawat, MD, head of global drug development at Novartis Oncology, said in a press release. “We look forward to working closely with the FDA over the coming months toward making crizanlizumab, a therapy that has the potential to prevent sickle cell pain crises, available in the U.S. as soon as possible.”